Accuray Inc (ARAY)
1.63
-0.04
(-2.40%)
USD |
NASDAQ |
May 17, 16:00
1.635
0.00 (0.00%)
After-Hours: 20:00
Accuray SG&A Expense (Quarterly): 22.73M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 22.73M |
December 31, 2023 | 24.58M |
September 30, 2023 | 23.27M |
June 30, 2023 | 23.95M |
March 31, 2023 | 22.19M |
December 31, 2022 | 25.62M |
September 30, 2022 | 22.69M |
June 30, 2022 | 26.40M |
March 31, 2022 | 20.97M |
December 31, 2021 | 23.95M |
September 30, 2021 | 22.73M |
June 30, 2021 | 24.23M |
March 31, 2021 | 21.85M |
December 31, 2020 | 20.68M |
September 30, 2020 | 17.79M |
June 30, 2020 | 22.30M |
March 31, 2020 | 20.00M |
December 31, 2019 | 21.21M |
September 30, 2019 | 23.88M |
June 30, 2019 | 26.62M |
March 31, 2019 | 24.67M |
December 31, 2018 | 25.61M |
September 30, 2018 | 28.68M |
June 30, 2018 | 30.30M |
March 31, 2018 | 26.16M |
Date | Value |
---|---|
December 31, 2017 | 25.71M |
September 30, 2017 | 26.06M |
June 30, 2017 | 27.11M |
March 31, 2017 | 24.21M |
December 31, 2016 | 24.27M |
September 30, 2016 | 25.66M |
June 30, 2016 | 26.10M |
March 31, 2016 | 26.23M |
December 31, 2015 | 27.76M |
September 30, 2015 | 26.83M |
June 30, 2015 | 27.08M |
March 31, 2015 | 24.65M |
December 31, 2014 | 28.16M |
September 30, 2014 | 28.92M |
June 30, 2014 | 29.54M |
March 31, 2014 | 26.42M |
December 31, 2013 | 25.45M |
September 30, 2013 | 25.81M |
June 30, 2013 | 25.32M |
March 31, 2013 | 29.39M |
December 31, 2012 | 31.65M |
September 30, 2012 | 25.73M |
June 30, 2012 | 30.12M |
March 31, 2012 | 26.41M |
December 31, 2011 | 27.41M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
17.79M
Minimum
Sep 2020
26.62M
Maximum
Jun 2019
22.88M
Average
22.73M
Median
SG&A Expense (Quarterly) Benchmarks
Boston Scientific Corp | 1.364B |
Integer Holdings Corp | 46.93M |
ResMed Inc | 229.92M |
Glaukos Corp | 61.98M |
Perspective Therapeutics Inc | 5.878M |